[Federal Register Volume 59, Number 162 (Tuesday, August 23, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-20825]
[[Page Unknown]]
[Federal Register: August 23, 1994]
_______________________________________________________________________
Part VI
Department of Health and Human Services
_______________________________________________________________________
National Institutes of Health
_______________________________________________________________________
Recombinant DNA Advisory Committee Meeting; Recombinant DNA Research:
Proposed Actions Under the Guidelines; Notices
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Recombinant DNA Advisory Committee; Notice of Meeting
Pursuant to Public Law 92-463, notice is hereby given of a meeting
of the Recombinant DNA Advisory Committee on September 12-13, 1994. The
meeting will be held at the National Institutes of Health, Building
31C, 6th Floor, Conference Room 6, 9000 Rockville Pike, Bethesda,
Maryland 20892, starting on September 12, 1994, at approximately 9
a.m., and will recess at approximately 6 p.m. The meeting will
reconvene on September 13, 1994, at approximately 8:30 a.m. and will
adjourn at approximately 5 p.m. The meeting will be open to the public
to discuss Proposed Actions under the NIH Guidelines for Research
Involving Recombinant DNA Molecules (59 FR 34496) and other matters to
be considered by the Committee. The Proposed Actions to be discussed
will follow this notice of meeting. Attendance by the public will be
limited to space available. Members of the public wishing to speak at
this meeting may be given such opportunity at the discretion of the
Chair.
In accordance with the provision set forth in sec. 552b(c)(4),
Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, the meeting will be
closed to the public on September 12 from 5 p.m., to approximately 6
p.m., for the review, discussion, and evaluation of proprietary
information which is a part of a human gene therapy research proposal.
The proposal and the discussion could reveal confidential trade secrets
or commercial property such as patentable material.
Dr. Nelson A. Wivel, Director, Office of Recombinant DNA
Activities, National Institutes of Health, Building 31, Room 4B11,
Bethesda, Maryland 20892, Phone (301) 496-9838, FAX (301) 496-9839,
will provide materials to be discussed at this meeting, roster of
committee members, and substantive program information. Individuals who
plan to attend and need special assistance, such as sign language
interpretation or other reasonable accommodations, should contact Dr.
Wivel in advance of the meeting. A summary of the meeting will be
available at a later date.
OMB's ``Mandatory Information Requirements for Federal Assistance
Program Announcements'' (45 FR 39592, June 11, 1980) requires a
statement concerning the official government programs contained in the
Catalog of Federal Domestic Assistance. Normally NIH lists in its
announcements the number and title of affected individual programs for
the guidance of the public. Because the guidance in this notice covers
not only virtually every NIH program but also essentially every Federal
research program in which DNA recombinant molecule techniques could be
used, it has been determined not to be cost effective or in the public
interest to attempt to list these programs. Such a list would likely
require several additional pages. In addition, NIH could not be certain
that every Federal program would be included as many Federal agencies,
as well as private organizations, both national and international, have
elected to follow the NIH Guidelines. In lieu of the individual program
listing, NIH invites readers to direct questions to the information
address above about whether individual programs listed in the Catalog
of Federal Domestic Assistance are affected.
Dated: August 3, 1994.
Susan K. Feldman,
Committee Management Officer, NIH.
[FR Doc. 94-20825 Filed 8-22-94; 8:45 am]
BILLING CODE 4141-01-M
